Revance Shares Fall on Failing to Bag FDA Approval




  • In Business
  • 2021-10-18 11:37:12Z
  • By SmarterAnalyst

Shares of Revance Therapeutics, Inc. (RVNC) dropped 33.1% in Friday's extended trade and another 32% at the time of writing after the company announced that the Food and Drug Administration (FDA) declined to approve its injectable drug, DaxibotulinumtoxinA, to treat moderate to severe glabellar (frown) lines.

The biotechnology company engages in the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. (See Revance stock charts on TipRanks)

FDA has reasoned that some shortcomings were identified in the Revance's manufacturing facility during the onsite inspection. Notably, no product-related deficiencies have been mentioned in the Complete Response Letter. The company seeks to request a Type A meeting with the FDA to address the deficiencies.

The President and CEO of Revance, Mark Foley, said, "We are very disappointed by this unanticipated response from the FDA and are seeking further clarity from the agency. We remain committed to bringing our next-generation neuromodulator product to market in both aesthetic and therapeutic indications."

Following the news, Mizuho Securities analyst Vamil Divan maintained a Buy rating on Revance and lowered the price target to $26 from $36. The new price target implies 14.5% upside potential from current level. (See Analysts' Top Stocks on TipRanks)

Divan noted, "We spoke to management over the weekend and assume this will likely mean a delay of about 12-15 months, but also believe Daxi is still approvable and will ultimately have an important role in the aesthetics and therapeutic toxin market."

Consensus among analysts is a Strong Buy based on 7 unanimous Buys. The average Revance price target of $25.50 implies upside potential of 12.3%.

Investors should always be aware of the risks involved in any stock. According to the new TipRanks' Risk Factors tool, RVNC is at risk mainly because of three factors: Legal and Regulatory, Finance and Corporate, and Tech & Innovation, which contribute 28%, 22% and 21%, respectively, to the total 67 risks identified for the stock. Under the Legal & Regulatory risk category, Revance has 19 risks, details of which can be found on the TipRanks website.

 

Related News:
Bank of America Reports Upbeat Q3 Results
Citigroup Q3 Results Beat Street Expectations
Corsair Expects Q3 Revenues to Miss Consensus Estimates; Shares Fall

More recent articles from Smarter Analyst:

  • Badger Meter Q3 Results Beat Expectations

  • Goldman Sachs Q3 Results Outperform; Shares Jump 3.8%

  • J.B. Hunt Exceeds Q3 Expectations; Shares Hit All-Time High

  • Truist Financial Posts Strong Q3 Results; Shares Rise 1.2%

COMMENTS

More Related News

CDC says all adults should get booster due to omicron variant: Latest COVID-19 updates
CDC says all adults should get booster due to omicron variant: Latest COVID-19 updates

The omicron variant causes the CDC to change its guidance on booster shots and unvaccinated federal workers get to keep their jobs for now. Updates.

Final US hurdle for Merck
Final US hurdle for Merck's COVID-19 pill: FDA panel review
  • World
  • 2021-11-30 14:10:35Z

An experimental COVID-19 drug that could soon become the first U.S.-authorized pill to treat the coronavirus faces one final hurdle Tuesday: A panel of...

Counterfeit COVID Masks Are Still Sold Everywhere, Despite Misleading Claims
Counterfeit COVID Masks Are Still Sold Everywhere, Despite Misleading Claims

The N95 mask, arguably the most essential and coveted piece of pandemic protective gear, is no longer a rare commodity, thanks to the return of Chinese imports and a resurgence in U.S. domestic production. But good luck buying them online or at big box retailers. Sign up for The Morning newsletter from the New York Times Consumers who try to purchase N95 masks, mainly on Amazon, are often led to vendors selling fake or poorly made KN95s, a Chinese-made mask that is often marketed as an N95 equiv

U.S. FDA panel to weigh Merck
U.S. FDA panel to weigh Merck's COVID-19 antiviral drug
  • US
  • 2021-11-30 11:03:46Z

A panel of expert advisers to the U.S. Food and Drug Administration will vote later on Tuesday on whether to recommend authorization of Merck & Co's...

Fact check: New ingredient in Pfizer COVID-19 vaccine mischaracterized in online posts
Fact check: New ingredient in Pfizer COVID-19 vaccine mischaracterized in online posts

Tris buffers do help maintain a vaccine's pH, or acidity, and stability, but there's nothing nefarious about the formulation switch.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • DASAPK
    (2021-10-18 14:19:52Z)

    يتم التحميل التطبيق بصيغة apk للاندرويد مجانا عبر الضغط على ايقونة التحميل فوق اعلاه وسيتم التحميل بشكل مجاني وامن

    REPLY

Top News: Business